Linda Hogan is Chief Business Officer at Palladio Biosciences. Linda brings to Palladio Biosciences over 35 years of experience in the health care industry, including biotech, venture capital, advisory services, and large pharma. She has focused primarily in the areas of product positioning, business strategy and corporate development.
She was most recently an officer and Vice President of Business Development and Strategy for CoLucid Pharmaceuticals, which was acquired by Eli Lilly in 2017 for approximately $960 million. As Executive in Residence at Care Capital, a venture capital firm, Linda sourced and evaluated potential investment opportunities, assisting with the startup of several portfolio companies. In 2006, she formed LLH Associates, LLC, a consulting firm which provides business development and strategic transaction support to clients. Previously, Linda completed a 20-year tenure with Aventis and its predecessor companies, during which she served in various roles of increasing responsibility in diverse functional areas, eventually becoming Vice President, Global Business Development for Aventis.
Prior to joining the pharmaceutical industry, Linda was Assistant Professor of Pharmacy Practice and Director of Drug Information Services for the University of Kansas School of Pharmacy and Kansas University Medical Center. Linda continued as Adjunct Associate Professor of Pharmacy Practice and served on the KU School of Pharmacy Advisory Council.
Professional awards include the TWIN (Tribute to Women in Industry) Award and the Donald E. Francke Award from the Drug Information Association. Linda received BS and MS degrees in Pharmacy and Hospital Pharmacy from the University of Kansas and an MBA from Rockhurst College.
Linda is a Life Sciences Council Member of Springboard Enterprises and active with the Licensing Executives Society.